SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Claire Thiriez, Emmanuel Itti, Gilles Fénelon, Eva Evangelista, Michel Meignan, Pierre Cesaro, Philippe Remy, Clinical routine use of dopamine transporter imaging in 516 consecutive patients, Journal of Neurology, 2015, 262, 4, 909

    CrossRef

  2. 2
    A. Skanjeti, T. Angusti, M. Iudicello, F. Dazzara, G. M. Delgado Yabar, E. Trevisiol, V. Podio, Assessing the Accuracy and Reproducibility of Computer-Assisted Analysis of 123I-FP-CIT SPECT Using BasGan (V2), Journal of Neuroimaging, 2014, 24, 3
  3. 3
    Joel S. Perlmutter, Scott A. Norris, Neuroimaging biomarkers for Parkinson disease: Facts and fantasy, Annals of Neurology, 2014, 76, 6
  4. 4
    Marios Politis, Neuroimaging in Parkinson disease: from research setting to clinical practice, Nature Reviews Neurology, 2014, 10, 12, 708

    CrossRef

  5. 5
    Anders Wimo, Dorota Religa, Kalle Spångberg, Ann-Katrin Edlund, Bengt Winblad, Maria Eriksdotter, Costs of diagnosing dementia: results from SveDem, the Swedish Dementia Registry, International Journal of Geriatric Psychiatry, 2013, 28, 10
  6. You have free access to this content6
    A. Berardelli, G. K. Wenning, A. Antonini, D. Berg, B. R. Bloem, V. Bonifati, D. Brooks, D. J. Burn, C. Colosimo, A. Fanciulli, J. Ferreira, T. Gasser, F. Grandas, P. Kanovsky, V. Kostic, J. Kulisevsky, W. Oertel, W. Poewe, J.-P. Reese, M. Relja, E. Ruzicka, A. Schrag, K. Seppi, P. Taba, M. Vidailhet, EFNS/MDS-ES recommendations for the diagnosis of Parkinson's disease, European Journal of Neurology, 2013, 20, 1
  7. 7
    Judith Dams, Bernhard Bornschein, Jens Peter Reese, Annette Conrads-Frank, Wolfgang H. Oertel, Uwe Siebert, Richard Dodel, Modelling the Cost Effectiveness of Treatments for Parkinsonʼs Disease, PharmacoEconomics, 2011, 29, 12, 1025

    CrossRef

  8. 8
    James Shearer, Colin Green, Carl E. Counsell, John P. Zajicek, The Use of Decision-Analytic Models in Parkinsonʼs Disease, Applied Health Economics and Health Policy, 2011, 9, 4, 243

    CrossRef

  9. 9
    Laura Silveira-Moriyama, Dharshana Sirisena, Pasan Gamage, Ranjanie Gamage, Rohan de Silva, Andrew J. Lees, Adapting the Sniffin' Sticks to diagnose Parkinson's disease in Sri Lanka, Movement Disorders, 2009, 24, 8
  10. 10
    C. Bairactaris, N. Demakopoulos, G. Tripsianis, C. Sioka, D. Farmakiotis, K. Vadikolias, I. Heliopoulos, P. Georgoulias, I. Tsougos, I. Papanastasiou, C. Piperidou, Impact of dopamine transporter single photon emission computed tomography imaging using I-123 ioflupane on diagnoses of patients with parkinsonian syndromes, Journal of Clinical Neuroscience, 2009, 16, 2, 246

    CrossRef

  11. 11
    A Jon Stoessl, Radionuclide scanning to diagnose Parkinson disease: is it cost-effective?, Nature Clinical Practice Neurology, 2009, 5, 1, 10

    CrossRef

  12. 12
    Angelo Antonini, Patrizia Berto, Stefania Lopatriello, Filippo Tamma, Lieven Annemans, Mike Chambers, Cost-effectiveness of 123I-FP-CIT SPECT in the differential diagnosis of essential tremor and Parkinson's disease in Italy, Movement Disorders, 2008, 23, 15
  13. 13
    Koen Van Laere, Ludwig Everaert, Lieven Annemans, Michel Gonce, Wim Vandenberghe, Thierry Vander Borght, The cost effectiveness of 123I-FP-CIT SPECT imaging in patients with an uncertain clinical diagnosis of parkinsonism, European Journal of Nuclear Medicine and Molecular Imaging, 2008, 35, 7, 1367

    CrossRef

  14. 14
    Christoph Scherfler, Johannes Schwarz, Angelo Antonini, Donald Grosset, Francesc Valldeoriola, Kenneth Marek, Wolfgang Oertel, Eduardo Tolosa, Andrew J. Lees, Werner Poewe, Role of DAT-SPECT in the diagnostic work up of Parkinsonism, Movement Disorders, 2007, 22, 9
  15. 15
    S. Hesse, C. Oehlwein, H. Barthel, J. Schwarz, D. Polster, A. Wagner, O. Sabri, Possible impact of dopamine SPECT on decision-making for drug treatment in Parkinsonian syndrome, Journal of Neural Transmission, 2006, 113, 9, 1177

    CrossRef